Alzheimer Therapeutics Market
Updated Date: 05 August 2026   |   Report Code: 5130
sales@towardshealthcare.com +1 804-441-9344
Download Sample Order Now

Alzheimer Therapeutics Market Size, Share, Trends and Forecast Analysis 2035

Based on market forecasts, the alzheimer’s therapeutics sector will expand from USD 5.7 billion in 2025 to USD 13.13 billion by 2035, experiencing a CAGR of 8.7%. In 2025, North America led the market, while Asia-Pacific is set for the fastest growth ahead. Cholinesterase inhibitors dominated by product, but pipeline drugs are expected to grow the quickest. Hospital pharmacies held the top spot among end-users, with e-commerce projected for strong future growth.

Last Updated : 05 August 2026 Category: Therapeutic Area Insight Code: 5130 Format: PDF / PPT / Excel

Content

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Alzheimer's Therapeutics Market Assessment

  • Overview
  • Global Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • Global Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce
  • Global Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

North America Alzheimer's Therapeutics Market Assessment

  • Overview
  • North America Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • North America Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

Europe Alzheimer's Therapeutics Market Assessment

  • Overview
  • Europe Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • Europe Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

Asia Pacific Alzheimer's Therapeutics Market Assessment

  • Overview
  • Asia Pacific Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • Asia Pacific Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

Middle East and Africa Alzheimer's Therapeutics Market Assessment

  • Overview
  • Middle East and Africa Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • Middle East and Africa Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

South America Alzheimer's Therapeutics Market Assessment

  • Overview
  • South America Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • South America Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

Company Profiles

  • Biogen Inc.
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Eli Lilly and Company
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc
  • AbbVie Inc.

Conclusion & Recommendations

FAQ's

Answer : The Alzheimer therapeutics market is expected to grow from USD 5.7 billion in 2025 to USD 13.13 billion by 2035, registering a CAGR of 8.7 driven by rising disease prevalence and innovation in treatment.

Answer : The driving factors of the Alzheimers therapeutics market include the aging population and ongoing innovation in treatment approaches.

Answer : World Health Organization, National Institute of Health, Food and Drug Administration, Centers for Disease Control and Prevention and Alzheimers Association.
Any Questions

Meet the Team

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar